Bellevue Group’s Asterias Biotherapeutics AST Stock Holding History
Bought
Maintained
Sold
Other funds holding AST
SM
Bellevue Group's AST Position: Q2 2016 in Review
Bellevue Group sold out of Asterias Biotherapeutics (AST) in Q2 2016, closing a stake of 1,875 shares — an estimated $9K sold.
Bellevue Group first reported a position in AST in Q1 2016 and held it in 1 quarter. The position peaked at $9K in Q1 2016. 66 funds tracked by Wall St. Rank hold AST as of Q2 2016.
- Bellevue Group reported no remaining Asterias Biotherapeutics position as of Q2 2016 after selling out during the quarter.
- Bellevue Group sold 1,875 Asterias Biotherapeutics shares in Q2 2016, an estimated $9K.
- Bellevue Group first reported a position in Asterias Biotherapeutics in Q1 2016 and held it in 1 quarter.
- Bellevue Group's Asterias Biotherapeutics position peaked at $9K in Q1 2016.
- 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics as of Q2 2016.
Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.